Belenos Biosciences Reports P-II Trial Results on BEL512 for CRSwNP

Shots: P-II trial, conducted by Belenos’partner Keymed Biosciences, assessed BEL512 (SC; 300mg, Q12W/Q24W or 600mg, Q24W) vs PBO, both on top of intranasal corticosteroid (QD), in 120 Chinese pts with CRSwNP with NPS of ≥5 (≥2 polyps/nostril) & a NCS of 2-3 Trial met its 1 & 2EPs, with the BEL512 showing statistically significant improvements…

ByRidhi Rastogi5 days ago

Know Your Investor: Perceptive Advisors (March’25 Edition)

Shots: The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com With…

ByPrince GiriMarch 20, 2025

Know Your Investor: Orbimed (February’ 25 Edition)

Shots: The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing For the complete report, contact us at connect@pharmashots.com OrbiMed primarily…

ByPrince GiriFebruary 6, 2025

Belenos Biosciences Reports P-II Trial Results on BEL512 for CRSwNP

Know Your Investor: Perceptive Advisors (March’25 Edition)

Know Your Investor: Orbimed (February’ 25 Edition)

Contact US

FOLLOW US